Quantcast
Home > Quotes > PSTI

Pluristem Therapeutics, Inc. Common Stock (PSTI) Quote & Summary Data

PSTI 
$1.09
*  
0.01
0.91%
Get PSTI Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading PSTI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PSTI Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3.5
Today's High / Low
$ 1.11 / $ 1.07
Share Volume
137,097
50 Day Avg. Daily Volume
226,811
Previous Close
$ 1.10
52 Week High / Low
$ 1.65 / $ 1.05
Market Cap
126,222,549
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.71

Intraday Chart

Shares Traded

Share Volume:
137,097
50 Day Avg. Daily Volume:
226,811

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.26

Trading Range

The current last sale of $1.09 is 3.81% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.11 $ 1.65
 Low: $ 1.07 $ 1.05

Company Description (as filed with the SEC)

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Our lead indications are critical limb ischemia, or CLI, recovery following surgery for hip fracture, and acute radiation syndrome, or ARS. Each of these indications is a severe unmet medical need. We were incorporated in Nevada in 2001, and have a wholly owned subsidiary in Israel called Pluristem Ltd., or the Subsidiary. We operate in one segment and our operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. PLX cells are derived from a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery of a baby. PLX cell products require no tissue matching prior to administration. They are produced using our proprietary three-dimensional expansion technology.  ... More ...  


Risk Grade

Where does PSTI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.11
Open Date:
Nov. 19, 2018
Close Price:
$ 1.09
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x